Home › Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting
 

Keywords :   


Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting

2015-11-16 14:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the companys C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens a regimen of grazoprevir1, MK-36822 and elbasvir3; and a regimen of grazoprevir, MK-3682 and MK-84084 in treatment-nave patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the results studies meeting

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Pork has its place in healthy, sustainable global diets
15.05Sontara Offers Sri Flo Wipes
15.05Iowa food pantries benefit from Pork in the Pantry donations
15.05NDSU to host animal disease emergency response preparedness
15.05NDSU to host animal disease emergency response preparedness
15.05Meat Institute updates Animal Handling Guidelines and Animal Welfare Audit
15.05Meat Institute updates Animal Handling Guidelines and Animal Welfare Audit
15.05Eastern North Pacific Tropical Weather Outlook
More »